Intravenous Immunoglobulin in Acute Immune Thrombocytopenia

Investigators from multiple institutions in the Netherlands conducted a randomized controlled trial to determine the effect of intravenous immunoglobulin (IVIG) treatment for immune thrombocytopenia (ITP) on the development of chronic ITP. Children were eligible if they were 3 months to 16 years old, had newly diagnosed ITP, had a platelet count of ≤20 × 10⁹/L, and had mild or moderate bleeding according to standardized bleeding score assessments. Participants were randomized to a treatment arm, in which they received a single dose (0.8 g/kg) of IVIG, or an observation arm, in which they were carefully observed and only received immunomodulatory treatment if they developed severe bleeding. Demographic and clinical data were collected at enrollment; data regarding symptoms, laboratory results, and clinical course were …